Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X6ZG
|
||||
| Former ID |
DIB010097
|
||||
| Drug Name |
XEN-D0101
|
||||
| Synonyms |
XEN-D101; Potassium channel Kv1.5 modulator (atrial fibillation), Xention
|
||||
| Indication | Atrial fibrillation [ICD9: 272, 427.31; ICD10:E78, I48] | Phase 1 | [1] | ||
| Company |
BioFocus DPI
|
||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily A member 5 | Target Info | Modulator | [2] | |
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Voltage gated Potassium channels | ||||
| WikiPathways | Potassium Channels | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018084) | ||||
| REF 2 | Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.